Abraxis BioScience

Abraxis BioScience
Industry Pharmaceutical
Founded 2007 (2007) in Los Angeles, California
Founder Dr. Patrick Soon-Shiong
Headquarters Los Angeles, USA
Key people
 Mr. Rick Click, Chief Information Officer and Global IT Officer; Dr. Nguyen V. Dat Ph.D., Vice President of Clinical Research
Products Protein-based therapeutics and technologies for treatment of cancer and other critical illnesses
Brands Abraxane
Services Cancer drugs
Owner Celgene
Website www.abraxisbio.com

Abraxis BioScience is a global biopharmaceutical company dedicated to meeting the needs of critically ill patients, with over 2000 employees worldwide.[1] Abraxis' portfolio includes the world's first protein-based nanoparticle chemotherapeutic compound called nab Technology.[2] From this the company has developed Abraxane, a treatment for metastatic breast cancer.[3] On June 30, 2010, it was announced that Abraxis BioScience would be acquired by Celgene Corporation.[4]

History

Restructure of 2007

In August 2007, Abraxis announced it would undergo a restructuring to separate it's "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research subunits to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., NASDAQ: ABII), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., NASDAQ: APPX).[5] This reorganization was completed in November 2007.[6] During the reorganization, the new Abraxis Bioscience was known briefly as "New Abraxis".[6]

References

  1. ↑ BioPortfolio, 2007, "InDepth Summary", 10/11/2009
  2. ↑ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
  3. ↑ Hoovers.
  4. ↑ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
  5. ↑ Van Arnum, Patricia (1 August 2007). "Abraxis BioScience Plans to Separate into Two Companies". Pharmaceutical Technology. Retrieved 2015-08-07 – via Highbeam Research.
  6. 1 2 Gopalakrishnan, Lisa (13 November 2007). FORM 8-K (Report). United States Securities and Exchange Commission. Retrieved 2015-08-07.

External links


This article is issued from Wikipedia - version of the Wednesday, February 10, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.